Ibotta IBTA
- Market cap
- $1.1B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $343.2M
- −7% on a year ago
- Net margin
- −3.2%
- Free cash flow yield
- 6.6%
Ibotta trades at 3.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $343.2M over the last twelve months, down 7% on a year earlier with a −3% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $85.3M | $99.7M | $82.3M+43% | $87.9M+14% | $98.6M+16% | $98.4M−1% | $84.6M+3% | $86M−2% | $83.3M−16% | $88.5M−10% | $82.5M−3% | $88.9M+3% | |
| Cost of revenue | $10.8M | $12.3M | $10.5M−7% | $12.3M+27% | $12.2M+13% | $15.2M+23% | $17.1M+63% | $17.9M+46% | $17.1M+41% | $18.9M+25% | $19.4M+14% | $19.2M+7% |
| Gross profit | $74.5M | $87.4M | $71.8M+55% | $75.6M+12% | $86.4M+16% | $83.2M−5% | $67.5M−6% | $68.1M−10% | $66.1M−24% | $69.6M−16% | $63M−7% | $69.7M+2% |
| R&D | $12.4M | $13.7M | $13.6M+17% | $17.5M+43% | $16.3M+31% | $15.8M+16% | $18.1M+33% | $14.7M−16% | $14M−14% | $14.2M−10% | $14.5M−20% | $15.1M+2% |
| SG&A | $49.7M | $46.8M | $41.3M+18% | $78.7M+125% | $48.4M−3% | $53.6M+15% | $51.2M+24% | $51.1M−35% | $49.1M+2% | $55.8M+4% | $57.8M+13% | $54.7M+7% |
| $10.9M | $26.3M | $15.9M | −$21.7M | $20.7M+91% | $13M−51% | −$2.8M | $1.2M | $2.4M−89% | −$1.6M | −$10.8M+286% | −$1.9M | |
| Interest expense | $2M | $2.9M | $2.8M+40% | $707K−64% | $39K−98% | $35K−99% | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | $7.8M | $22.3M | $12.4M | −$30M | $25.1M+222% | $17M−24% | $483K−96% | $3.9M | $5.3M−79% | $244K−99% | −$9.4M | −$532K |
| −$610K | $3.7M | $3.1M+1768% | $3.9M+46% | $7.9M | −$59.2M | −$72K | $1.4M−65% | $3.7M−53% | $1.2M | $969K | $697K−49% | |
| Net income | $8.4M | $18.6M | $9.3M | −$34M | $17.2M+105% | $76.2M+309% | $555K−94% | $2.5M | $1.5M−91% | −$1M | −$10.3M | −$1.2M |
| $0.31 | $0.67 | $0.33 | −$1.32 | $0.51+65% | $2.28+240% | $0.02−94% | $0.08 | $0.05−90% | −$0.04 | −$0.43 | −$0.05 | |
| 26.8M | 27.8M | 28.4M+222% | 25.7M−3% | 33.6M+25% | 33.5M+20% | 33.2M+17% | 30.4M+19% | 29.4M−13% | 26.3M−22% | 24.1M−27% | 23.3M−24% |
EPS, diluted: 3 periods, Q4 FY23 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Software - Application nearest Ibotta's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IBTAIbotta | $1.1B | n/m | 26.1× | 3.3× | −7% | −3.2% | |
| UPWKUpwork | $1.2B | 12.5× | 15.9× | 1.5× | +2% | 12.9% | |
| LZLegalzoom.Com | $1.2B | 77.7× | 68.5× | 1.5× | +12% | 2.1% | |
| GDRXGoodRx | $1.2B | 88.5× | 55.6× | 1.5× | −2% | 2.1% | |
| HSTMHealthstream | $1B | 48.8× | 54.3× | 3.2× | +9% | 6.6% | |
| EVEREverQuote | $801.4M | 7.4× | 18.5× | 1.1× | +23% | 15.2% | |
| TASKTaskUs | $784.8M | 7.4× | 26.3× | 0.6× | +11% | 8.8% | |
| YEXTYext | $727.5M | 38.7× | 48.3× | 1.6× | −1% | 5.9% | |
| MNTNMNTN | $724.1M | 12.9× | 15.1× | 2.3× | +21% | 18.0% | |
| NRDSNerdwallet | $698.7M | 12.3× | 15.9× | 0.8× | +12% | 7.6% | |
| EVTCEVERTEC | $1.9B | 21.1× | 20.9× | 1.9× | +12% | 9.8% | |
| Peer median | $914.7M | 17.0× | 23.6× | 1.5× | +11% | 8.2% |
More on Ibotta
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Software - Application
- Sector
- Technology
Valuation data, not investment advice. Prices as of .